Horizon Therapeutics PLC (NASDAQ:HZNP) Chairman Timothy P. Walbert Sells 58,820 Shares

Horizon Therapeutics PLC (NASDAQ:HZNP) Chairman Timothy P. Walbert sold 58,820 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $28.00, for a total value of $1,646,960.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Timothy P. Walbert also recently made the following trade(s):

  • On Wednesday, August 21st, Timothy P. Walbert sold 56,836 shares of Horizon Therapeutics stock. The shares were sold at an average price of $28.00, for a total value of $1,591,408.00.

Shares of HZNP opened at $27.19 on Friday. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 1.64 and a beta of 0.88. The stock has a 50 day moving average of $25.07 and a 200-day moving average of $25.19. The company has a current ratio of 2.20, a quick ratio of 2.12 and a debt-to-equity ratio of 0.90. Horizon Therapeutics PLC has a 52 week low of $16.56 and a 52 week high of $29.44.

Horizon Therapeutics (NASDAQ:HZNP) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.38 by $0.14. The company had revenue of $320.60 million during the quarter, compared to analyst estimates of $296.27 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 EPS. On average, sell-side analysts predict that Horizon Therapeutics PLC will post 1.6 earnings per share for the current fiscal year.

HZNP has been the subject of several research reports. BMO Capital Markets upgraded Horizon Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $29.00 to $36.00 in a research report on Wednesday, August 14th. TheStreet lowered Horizon Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, June 10th. Citigroup upgraded Horizon Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $21.00 to $32.00 in a research report on Wednesday, May 1st. Mizuho set a $27.00 target price on Horizon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Finally, BidaskClub upgraded Horizon Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $32.73.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Daiwa Securities Group Inc. bought a new stake in shares of Horizon Therapeutics in the 1st quarter worth approximately $29,000. Manchester Capital Management LLC bought a new stake in shares of Horizon Therapeutics in the 1st quarter worth approximately $41,000. Quadrant Capital Group LLC bought a new stake in shares of Horizon Therapeutics in the 1st quarter worth approximately $53,000. New York State Teachers Retirement System bought a new stake in shares of Horizon Therapeutics in the 2nd quarter worth approximately $55,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in shares of Horizon Therapeutics in the 2nd quarter worth approximately $76,000. 86.46% of the stock is currently owned by institutional investors and hedge funds.

Horizon Therapeutics Company Profile

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Further Reading: Leveraged Buyout (LBO) Explained

Insider Buying and Selling by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.